Clodronate plus CMF

A combination therapy used in a clinical study for premenopausal breast cancer patients. It consists of the CMF chemotherapy regimen (cyclophosphamide, methotrexate, and fluorouracil) combined with clodronate, a bisphosphonate. The CMF regimen involves cyclophosphamide (an alkylating agent that stops cancer cells from reproducing), methotrexate (an antimetabolite that stops cells from making and fixing DNA), and fluorouracil (5-FU, another antimetabolite that stops cells from making and repairing DNA). Clodronate was added to prevent bone loss associated with chemotherapy-induced ovarian failure. The study demonstrated that clodronate significantly reduced bone loss in patients who developed amenorrhea after chemotherapy. For instance, at 2 years, lumbar spine bone loss was reduced from 9.5% to 5.9%, and femoral neck bone loss from 4.6% to 0.4% in the clodronate group compared to control. This combination was specifically investigated for premenopausal breast cancer patients receiving adjuvant chemotherapy, particularly women over 40 years, who are at high risk for rapid bone loss. Clodronate was administered either orally at 1,600 mg/day or as intravenous intermittent infusions (1,500 mg each) parallel to the chemotherapy.

Other names

Clodronate + CMF regimen